C4 Therapeutics Inc (CCCC) — Capital Reinvestment Ratio
Latest as of June 2019:
0.02x
C4 Therapeutics Inc (CCCC) has a Capital Reinvestment Ratio of 0.02x as of June 2019, meaning it reinvests 0% of its operating cash flow ($36.91 Million) in capital expenditures ($641.00K). See C4 Therapeutics Inc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.02x
Capex / Operating Cash Flow
Operating Cash Flow
$36.91 Million
USD
Capital Expenditures
$641.00K
USD
Data as of
Jun 2019
Most recent filing
C4 Therapeutics Inc Capital Reinvestment Ratio (2019–2019)
This chart tracks C4 Therapeutics Inc's Capital Reinvestment Ratio across 1 annual periods.
Annual Capital Reinvestment Ratio for C4 Therapeutics Inc (2019–2019)
Year-by-year Capital Reinvestment Ratio for C4 Therapeutics Inc from 2019 to 2019. For live market cap and broader valuation context, see CCCC market cap overview.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2019 | 0.02x | $55.61 Million | $1.35 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow